A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19

NCT04869592 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

3100

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
BIOLOGICAL: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
BIOLOGICAL: placebo

Sponsor

National Vaccine and Serum Institute, China

Collaborators

[object Object]
[object Object]
[object Object]